The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
Open accessAbstract
BACKGROUND: A trial involving adults 50 years of age or older (ZOE-50) showed that the herpes zoster subunit vaccine (HZ/su) containing recombinant varicella-zoster virus glycoprotein E and the AS01B adjuvant system was associated with a risk of herpes zoster that was 97.2% lower than that associated with placebo. A second trial was performed concurrently at the same sites and examined the safety and efficacy of HZ/su in adults 70 years of age or older (ZOE-70). METHODS: This randomized, placebo-controlled, phase 3 trial was conducted in 18 countries and involved adults 70 years of age or older. Participants received two doses of HZ/su or placebo (assigned in a 1:1 ratio) administered intramuscularly 2 months apart. Vaccine efficacy against herpes zoster and postherpetic neuralgia was assessed in participants from ZOE-70 and in participants pooled from ZOE-70 and ZOE-50. RESULTS: In ZOE-70, 13,900 participants who could be evaluated (mean age, 75.6 years) received either HZ/su (6950 participants) or placebo (6950 participants). During a mean follow-up period of 3.7 years, herpes zoster occurred in 23 HZ/su recipients and in 223 placebo recipients (0.9 vs. 9.2 per 1000 person-years). Vaccine efficacy against herpes zoster was 89.8% (95% confidence interval [CI], 84.2 to 93.7; P<0.001) and was similar in participants 70 to 79 years of age (90.0%) and participants 80 years of age or older (89.1%). In pooled analyses of data from participants 70 years of age or older in ZOE-50 and ZOE-70 (16,596 participants), vaccine efficacy against herpes zoster was 91.3% (95% CI, 86.8 to 94.5; P<0.001), and vaccine efficacy against postherpetic neuralgia was 88.8% (95% CI, 68.7 to 97.1; P<0.001). Solicited reports of injection-site and systemic reactions within 7 days after injection were more frequent among HZ/su recipients than among placebo recipients (79.0% vs. 29.5%). Serious adverse events, potential immune-mediated diseases, and deaths occurred with similar frequencies in the two study groups. CONCLUSIONS: In our trial, HZ/su was found to reduce the risks of herpes zoster and postherpetic neuralgia among adults 70 years of age or older. (Funded by GlaxoSmithKline Biologicals; ZOE-50 and ZOE-70 ClinicalTrials.gov numbers, NCT01165177 and NCT01165229 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The degree of reactogenicity after one dose of mRNA-1273 was less than that observed for the recently approved recombinant adjuvanted zoster vaccine and after the second mRNA-1273 dose was similar to that of the zoster vaccine. 21,22”
From Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine (2021) · cites this paper as [21]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Vaccination against VZV is considered an effective approach to reduce the risk of shingles32.”
From Algorithm for optimized mRNA design improves stability and immunogenicity (2023) · cites this paper as [32]
In the citing paper
“the AS01B-adjuvanted VZV gE subunit vaccine was highly effective irrespective of age”
From Successful and Maladaptive T Cell Aging (2017) · cites this paper as Cunningham et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The burden of disease in older people and implications for health policy and practice
Prince, M. J., Wu, F., Guo, Y., Gutiérrez‐Robledo, L. M., O'Donnell, M. J., Sullivan, R. J., & Yusuf, S. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61347-7 · Cited by 2,473
A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
Oxman, M. N., Levin, M. J., Johnson, G. R., Schmader, K. E., Straus, S. E., Gelb, L. D., Arbeit, R. D., Simberkoff, M. S., Gershon, A. A., Davis, L. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051016 · Cited by 2,412
Self-citationEfficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Lal, H., Cunningham, A. L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.-J., Levin, M. J., McElhaney, J. E., Poder, A., Puig-Barberà, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501184 · Cited by 1,454
Self-citationSystematic review of incidence and complications of herpes zoster: towards a global perspective
Kawai, K., Gebremeskel, B. G., & Acosta, C. J. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-004833 · Cited by 943
Yawn, B. P., Saddier, P., Wollan, P. C., Sauver, J. L. S., Kurland, M. J., & Sy, L. S. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.11.1341 · Cited by 866
A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
The RTS, S. C. T. P. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208394 · Cited by 752
Cohen, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmcp1302674 · Cited by 737
Johnson, R. W., & Rice, A. S. C. (2014) · New England Journal of Medicine · doi:10.1056/nejmcp1403062 · Cited by 575
The incidence of herpes zoster in a United States administrative database
Insinga, R. P., Itzler, R. F., Pellissier, J. M., Saddier, P., & Nikas, A. A. (2005) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2005.0150.x · Cited by 490
Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems
Garçon, N., & Mechelen, M. V. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.29 · Cited by 318
Flagged first, then by citations
Research works printed but not linked: 3
- Harpaz R, 2008, MMWR Recomm Rep, 57, 1
- Chen N, 2014, Cochrane Database Syst Rev, CD006866
- 2011, MMWR Morb Mortal Wkly Rep, 60, 1528
Cited by
Sorted by citations
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Colloca, L., Ludman, T., Bouhassira, D., Baron, R., Dickenson, A. H., Yarnitsky, D., Freeman, R. L., Truini, A., Attal, N., Finnerup, N. B., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.2 · Cited by 2,271
Neuropathic Pain: From Mechanisms to Treatment
Finnerup, N. B., Kuner, R., & Jensen, T. S. (2020) · Physiological Reviews · doi:10.1152/physrev.00045.2019 · Cited by 1,727
Furer, V., Rondaan, C., Heijstek, M. W., Agmon‐Levin, N., van Assen, S., Bijl, M., Breedveld, F. C., D’Amelio, R., Dougados, M., Kapetanovic, M. C., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215882 · Cited by 859
Dooling, K. L., Guo, A., Patel, M., Lee, G. M., Moore, K. L., Belongia, E. A., & Harpaz, R. (2018) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6703a5 · Cited by 633
Correlates of adjuvanticity: A review on adjuvants in licensed vaccines
Giudice, G. D., Rappuoli, R., & Didierlaurent, A. M. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.05.001 · Cited by 631
Immunosenescence and human vaccine immune responses
Crooke, S. N., Ovsyannikova, I. G., Poland, G. A., & Kennedy, R. B. (2019) · Immunity & Ageing · doi:10.1186/s12979-019-0164-9 · Cited by 530
The how’s and what’s of vaccine reactogenicity
Hervé, C., Laupèze, B., Giudice, G. D., Didierlaurent, A. M., & Silva, F. T. D. (2019) · npj Vaccines · doi:10.1038/s41541-019-0132-6 · Cited by 514
The role of vaccines in combatting antimicrobial resistance
Micoli, F., Bagnoli, F., Rappuoli, R., & Serruto, D. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00506-3 · Cited by 504
Algorithm for optimized mRNA design improves stability and immunogenicity
Zhang, H., Zhang, L., Lin, A., Xu, C., Li, Z., Liu, K., Liu, B., Ma, X., Zhao, F., Jiang, H., et al. (2023) · Nature · doi:10.1038/s41586-023-06127-z · Cited by 531
Surveillance of vaccination coverage among adult populations—United States, 2015.
Williams, W. W., Lu, P.-J., O’Halloran, A., Kim, D. K., Grohskopf, L. A., Pilishvili, T., Skoff, T. H., Nelson, N. P., Harpaz, R., Markowitz, L. E., et al. (2017) · MMWR Surveillance Summaries · doi:10.15585/mmwr.ss6611a1 · Cited by 442
Vaccination in the elderly: The challenge of immune changes with aging
Ciabattini, A., Nardini, C., Santoro, F., Garagnani, P., Franceschi, C., & Medaglini, D. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.10.010 · Cited by 411
Analytical characterization of liposomes and other lipid nanoparticles for drug delivery
Fan, Y., Marioli, M., & Zhang, K. (2020) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2020.113642 · Cited by 427
Successful and Maladaptive T Cell Aging
Goronzy, J. J., & Weyand, C. M. (2017) · Immunity · doi:10.1016/j.immuni.2017.03.010 · Cited by 362
Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Chauhan, G., Madou, M. J., Kalra, S., Chopra, V., Ghosh, D., & Martinez-Chapa, S. O. (2020) · ACS Nano · doi:10.1021/acsnano.0c04006 · Cited by 387
Clinical Features of Varicella-Zoster Virus Infection
Kennedy, P. G. E., & Gershon, A. A. (2018) · Viruses · doi:10.3390/v10110609 · Cited by 368
The structural basis of herpesvirus entry
Connolly, S. A., Jardetzky, T. S., & Longnecker, R. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00448-w · Cited by 366
Understanding modern-day vaccines: what you need to know
Vetter, V., Denizer, G., Friedland, L. R., Krishnan, J., & Marla Shapiro, C. M. (2017) · Annals of Medicine · doi:10.1080/07853890.2017.1407035 · Cited by 355
Cordonnier, C., Einarsdottir, S., Cesaro, S., Blasi, R. D., Mikulska, M., Rieger, C. T., de Lavallade, H., Gallo, G., Lehrnbecher, T., Engelhard, D., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30600-5 · Cited by 334
Risk Factors for Herpes Zoster: A Systematic Review and Meta-analysis
Kawai, K., & Yawn, B. P. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.10.009 · Cited by 312
Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization
Wang, N., Chen, M., & Wang, T. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.04.025 · Cited by 313
Kim, D. K., Riley, L. E., Harriman, K. H., Hunter, P. H., & Bridges, C. B. (2017) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6605e2 · Cited by 309
Influence of immune aging on vaccine responses
Gustafson, C. E., Kim, C., Weyand, C. M., & Goronzy, J. J. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.03.017 · Cited by 292
Human T cell immunosenescence and inflammation in aging
Bektas, A., Schurman, S. H., Sen, R., & Ferrucci, L. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ri0716-335r · Cited by 274
Bastidas, A., de la Serna, J., Idrissi, M. E., Oostvogels, L., Quittet, P., López‐Jiménez, J., Vural, F., Pohlreich, D., Zuckerman, T., Issa, N. C., et al. (2019) · JAMA · doi:10.1001/jama.2019.9053 · Cited by 269
Self-citationOh, S. J., Lee, J. K., & Shin, O. S. (2019) · Immune Network · doi:10.4110/in.2019.19.e37 · Cited by 264
Dagnew, A. F., İlhan, O., Lee, W. S., Woszczyk, D., Kwak, J., Bowcock, S. J., Sohn, S. K., Macias, G. R., Chiou, T.-J., Quiel, D., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30163-x · Cited by 256
Self-citationControlling timing and location in vaccines
Irvine, D. J., Aung, A., & Silva, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.019 · Cited by 255
Structure-Based Vaccine Antigen Design
Graham, B. S., Gilman, M. S. A., & McLellan, J. S. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-121217-094234 · Cited by 234
Herpes Zoster in the Older Adult
John, A., & Canaday, D. H. (2017) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2017.07.016 · Cited by 220
Technologies to address antimicrobial resistance
Baker, S. J., Payne, D. J., Rappuoli, R., & Gregorio, E. D. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717160115 · Cited by 219
Vaccination of special populations: Protecting the vulnerable
Doherty, M., Schmidt-Ott, R., Santos, J. I., Stanberry, L. R., Hofstetter, A. M., Rosenthal, S. L., & Cunningham, A. L. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.11.015 · Cited by 208
Self-citationCunningham, A. L., Heineman, T. C., Lal, H., Godeaux, O., Chlíbek, R., Hwang, S., McElhaney, J. E., Vesikari, T., Andrews, C. P., Choi, W. S., et al. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy095 · Cited by 205
Self-citationHarbecke, R., Cohen, J. I., & Oxman, M. N. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab387 · Cited by 200
Vink, P., Ramon, J. M., Sánchez-Fructuoso, A. I., Kim, S.-J., Kim, S.-I., Zaltzman, J. S., Ortiz, F., Campistol, J. M., Rodríguez, A. M. F., Rodrigo, H. R., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz177 · Cited by 199
Self-citationVaccine development for respiratory syncytial virus
Graham, B. S. (2017) · Current Opinion in Virology · doi:10.1016/j.coviro.2017.03.012 · Cited by 198
Personalized vaccinology: A review
Poland, G. A., Ovsyannikova, I. G., & Kennedy, R. B. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.07.062 · Cited by 203
Lacaille‐Dubois, M. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.152905 · Cited by 183
Targeting Inflammation and Immunosenescence to Improve Vaccine Responses in the Elderly
Pereira, B. I., Xu, X., & Akbar, A. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583019 · Cited by 190
Vaccines for preventing herpes zoster in older adults
Gagliardi, A. M., Andriolo, B. N., Torloni, M. R., & Soares, B. G. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008858.pub3 · Cited by 175
Antiviral Therapies for Herpesviruses: Current Agents and New Directions
Poole, C. L., & James, S. H. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.07.006 · Cited by 175
Vaccines for the elderly: current use and future challenges
Weinberger, B. (2018) · Immunity & Ageing · doi:10.1186/s12979-017-0107-2 · Cited by 168
Tricco, A. C., Zarin, W., Cardoso, R., Veroniki, A. A., Khan, P. A., Nincic, V., Ghassemi, M., Warren, R., Sharpe, J. P., Page, A. V., et al. (2018) · BMJ · doi:10.1136/bmj.k4029 · Cited by 168
Infections in the Elderly Critically-Ill Patients
Eşme, M., Topeli̇, A., Doğu, B. B., & Akova, M. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00118 · Cited by 157
Rondaan, C., Furer, V., Heijstek, M. W., Agmon-Levin, N., Bijl, M., Breedveld, F. C., D’Amelio, R., Dougados, M., Kapetanovic, M. C., van Laar, J. M., et al. (2019) · RMD Open · doi:10.1136/rmdopen-2019-001035 · Cited by 154
Rieger, C. T., Liss, B., Mellinghoff, S. C., Buchheidt, D., Cornely, O. A., Egerer, G., Heinz, W., Hentrich, M., Maschmeyer, G., Mayer, K. T., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy117 · Cited by 155
A malaria vaccine adjuvant based on recombinant antigen binding to liposomes
Huang, W.-C., Deng, B., Lin, C., Carter, K. A., Geng, J., Razi, A., He, X., Chitgupi, U., Federizon, J., Sun, B., et al. (2018) · Nature Nanotechnology · doi:10.1038/s41565-018-0271-3 · Cited by 148
Burny, W., Callegaro, A., Bechtold, V., Clément, F., Delhaye, S., Fissette, L. A., Janssens, M., Leroux-Roels, G. G., Marchant, A., van den Berg, R. A., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00943 · Cited by 151
Crooke, S. N., Ovsyannikova, I. G., Poland, G. A., & Kennedy, R. B. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.110632 · Cited by 146
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
Ludwig, H., Boccadoro, M., Moreau, P., Miguel, J. F. S., Cavo, M., Pawlyn, C., Zweegman, S., Facon, T. T. F., Driessen, C., Hájek, R., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01016-0 · Cited by 142
Lopez, A., Xavier Mariette, A., Bachelez, H., Bélot, A., Bonnotte, B., HACHULLA, E., Lahfa, M., Lortholary, O., Loulergue, P., Paul, S., et al. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.03.011 · Cited by 138
Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure
Izurieta, H. S., Wu, X., Forshee, R. A., Lu, Y., Sung, H.-M., Agger, P. E., Chillarige, Y., Link‐Gelles, R., Lufkin, B., Wernecke, M., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab125 · Cited by 137
Deploy vaccines to fight superbugs
Rappuoli, R., Bloom, D. E., & BLACK, S. B. (2017) · Nature · doi:10.1038/d41586-017-08323-0 · Cited by 132
The safety of JAK-1 inhibitors
Clarke, B. D., Yates, M., Adas, M. A., Bechman, K., & Galloway, J. B. (2021) · Lara D. Veeken · doi:10.1093/rheumatology/keaa895 · Cited by 132
Pergam, S. A., Limaye, A. P., & Practice, T. A. I. D. C. O. (2019) · Clinical Transplantation · doi:10.1111/ctr.13622 · Cited by 128
Heineman, T. C., Cunningham, A. L., & Levin, M. J. (2019) · Current Opinion in Immunology · doi:10.1016/j.coi.2019.02.009 · Cited by 127
Self-citationShingrix: The New Adjuvanted Recombinant Herpes Zoster Vaccine
James, S. F., Chahine, E. B., Sucher, A. J., & Hanna, C. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018758431 · Cited by 126
Vink, P., Mingorance, I. D., Maximiano, C., Rubio‐Viqueira, B., Jung, K. H., Rodríguez-Moreno, J. F., Grande, E., Marrupe, D., Lowndes, S. A., Puente, J., et al. (2019) · Cancer · doi:10.1002/cncr.31909 · Cited by 126
Self-citationRedelman‐Sidi, G., Michielin, O. A., Cervera, C., Ribi, C., Aguado, J. M., Fernández‐Ruiz, M., & Manuel, O. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.030 · Cited by 127
Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies
Papp, K. A., Haraoui, B. P., Kumar, D., Marshall, J. K., Bissonnette, R., Bitton, A., Bressler, B. L., Gooderham, M., HO, V. C., Jamal, S., et al. (2018) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475418811335 · Cited by 124
Toward precision adjuvants: optimizing science and safety
Nanishi, E., Dowling, D. J., & Levy, O. (2020) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000868 · Cited by 130
Nanishi, E., Borriello, F., O’Meara, T. R., McGrath, M. E., Saito, Y., Haupt, R. E., Seo, H., van Haren, S. D., Cavazzoni, C. B., Brook, B., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj5305 · Cited by 123
Yang, J., Tseng, J., Yu, G., Luo, Y., Huang, C. F., Hong, Y., & Chuang, T. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020423 · Cited by 129
Herpes zoster – typical and atypical presentations
Dayan, R. R., & Peleg, R. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1335574 · Cited by 122
Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review
Pan, C. X., Lee, M. S., & Nambudiri, V. E. (2022) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355221084535 · Cited by 122
Chong, P. P., & Avery, R. K. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.07.005 · Cited by 120
Wagner, A., & Weinberger, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00717 · Cited by 127
Pardo, G., & Jones, D. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8594-9 · Cited by 124
A spliced latency-associated VZV transcript maps antisense to the viral transactivator gene 61
Depledge, D. P., Ouwendijk, W. J. D., Sadaoka, T., Braspenning, S. E., Mori, Y., Cohrs, R. J., Verjans, G. M. G. M., & Breuer, J. (2018) · Nature Communications · doi:10.1038/s41467-018-03569-2 · Cited by 119
Schmader, K. E. (2018) · Annals of Internal Medicine · doi:10.7326/aitc201808070 · Cited by 117
Vaccine adjuvants: Tailoring innate recognition to send the right message
Lavelle, E. C., & McEntee, C. P. (2024) · Immunity · doi:10.1016/j.immuni.2024.03.015 · Cited by 124
The infection risks of JAK inhibition
Adas, M. A., Alveyn, E., Cook, E., Dey, M., Galloway, J. B., & Bechman, K. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2014323 · Cited by 116
Colombel, J. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy150 · Cited by 115
Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2018*
Kim, D. K., Riley, L. E., & Hunter, P. H. (2018) · Annals of Internal Medicine · doi:10.7326/m17-3439 · Cited by 114
Central nervous system infections produced by varicella zoster virus
Nagel, M. A., Niemeyer, C. S., & Bubak, A. N. (2020) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000647 · Cited by 114
Thompson, R. R., Kong, C., Porco, T. C., Kim, E. H., Ebert, C. D., & Acharya, N. R. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1185 · Cited by 113
Tseng, H. F., Bruxvoort, K. J., Ackerson, B. K., Luo, Y., Tanenbaum, H. C., Tian, Y., Zheng, C., Cheung, B., Patterson, B. J., Oorschot, D. V., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz652 · Cited by 111
The continued advance of vaccine adjuvants – ‘we can work it out’
O’Hagan, D. T., Lodaya, R. N., & Lofano, G. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101426 · Cited by 115
Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention
Lecrenier, N., Beukelaers, P., Colindres, R. E., Curran, D., Kesel, C. D., Saegher, J.-P. D., Didierlaurent, A. M., Ledent, E., Mols, J., Mrkvan, T., et al. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1495565 · Cited by 111
Self-citationClinical presentation, management, and pathophysiology of neuropathic itch
Steinhoff, M. S., Schmelz, M., Szabó, I. L., & Oaklander, A. L. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30217-5 · Cited by 109
Strezova, A., Díez‐Domingo, J., Shawafi, K. A., Tinoco, J. C., Shi, M., Pirrotta, P., Mwakingwe-Omari, A., Zoster-049 Study Group, Adams, M. A., Ahonen, A., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac485 · Cited by 103
Self-citationLiposomes as Adjuvants and Vaccine Delivery Systems
Tretiakova, D. S., & Vodovozova, E. L. (2022) · Biochemistry (Moscow) Supplement Series A Membrane and Cell Biology · doi:10.1134/s1990747822020076 · Cited by 109
Nanocarrier vaccines for SARS-CoV-2
Machhi, J., Shahjin, F., Das, S., Patel, M., Abdelmoaty, M. M., Cohen, J. D., Singh, P. A., Baldi, A., Bajwa, N., Kumar, R., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.002 · Cited by 100
Adjuvant system AS01: from mode of action to effective vaccines
Roman, F. P., Burny, W., Ceregido, M. A., Laupèze, B., Temmerman, S. T., Warter, L., & Coccia, M. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2382725 · Cited by 115
Sun, Y., Kim, E. H., Kong, C., Arnold, B. F., Porco, T. C., & Acharya, N. R. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab121 · Cited by 98
Recombinant Zoster Vaccine (Shingrix®): A Review in Herpes Zoster
Syed, Y. Y. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0603-x · Cited by 97
Le, P., & Rothberg, M. B. (2019) · BMJ · doi:10.1136/bmj.k5095 · Cited by 96
Boutry, C., Hastie, A., Díez‐Domingo, J., Tinoco, J. C., Yu, C., Andrews, C. P., Beytout, J., Caso, C., Cheng, H., Cheong, H. J., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab629 · Cited by 96
Self-citationMa, C., Lee, J. K., Mitra, A. R., Teriaky, A., Choudhary, D., Nguyen, T. M., Casteele, N. V., Khanna, R., Panaccione, R., Feagan, B. G., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15297 · Cited by 96
Th1 memory differentiates recombinant from live herpes zoster vaccines
Levin, M. J., Kroehl, M., Johnson, M. J., Hammes, A., Reinhold, D., Lang, N., & Weinberg, A. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121484 · Cited by 93
Self-citationFighting against a protean enemy: immunosenescence, vaccines, and healthy aging
Giudice, G. D., Goronzy, J. J., Grubeck‐Loebenstein, B., Lambert, P., Mrkvan, T., Stoddard, J. J., & Doherty, T. M. (2017) · npj Aging and Mechanisms of Disease · doi:10.1038/s41514-017-0020-0 · Cited by 91
Fostering healthy aging: The interdependency of infections, immunity and frailty
Vetrano, D. L., Triolo, F., Maggi, S., Malley, R., Jackson, T., Poscia, A., Bernabei, R., Ferrucci, L., & Fratiglioni, L. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101351 · Cited by 97
Mbinta, J. F., Nguyen, B. P., Awuni, P. M. A., Paynter, J., & Simpson, C. R. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(22)00039-3 · Cited by 93
Adjuvant strategies to improve vaccination of the elderly population
Weinberger, B. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.03.014 · Cited by 87
Amirthalingam, G., Andrews, N., Keel, P., Mullett, D., Correa, A., de Lusignan, S., & Ramsay, M. E. (2017) · The Lancet Public Health · doi:10.1016/s2468-2667(17)30234-7 · Cited by 85
Urgency and necessity of Epstein-Barr virus prophylactic vaccines
Zhong, L., Krummenacher, C., Zhang, W., Hong, J., Feng, Q., Chen, Y., Zhao, Q., Zeng, M., Zeng, Y., Xu, M., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00587-6 · Cited by 88
Herpes Simplex Virus and Varicella Zoster Virus Infections in Cancer Patients
Tayyar, R., & Ho, D. Y. (2023) · Viruses · doi:10.3390/v15020439 · Cited by 85
Challenges in adult vaccination
de Gomensoro, E., Giudice, G. D., & Doherty, T. M. (2018) · Annals of Medicine · doi:10.1080/07853890.2017.1417632 · Cited by 85
Immunostimulatory Polymers as Adjuvants, Immunotherapies, and Delivery Systems
Weiss, A. M., Hossainy, S., Rowan, S. J., Hubbell, J. A., & Esser-Kahn, A. P. (2022) · Macromolecules · doi:10.1021/acs.macromol.2c00854 · Cited by 89
The temporal impact of aging on the burden of herpes zoster
Varghese, L., Standaert, B. A., Olivieri, A., & Curran, D. (2017) · BMC Geriatrics · doi:10.1186/s12877-017-0420-9 · Cited by 84
Metadata
- Authors
- Cunningham, A. L., Lal, H., Kovac, M., Chlibek, R., Hwang, S.-J., Díez-Domingo, J., Godeaux, O., Levin, M. J., McElhaney, J. E., Puig-Barberà, J., Vanden Abeele, C., Vesikari, T., Watanabe, D., Zahaf, T., Ahonen, A., Athan, E., Barba-Gomez, J. F., Campora, L., de Looze, F., Downey, H. J., Ghesquiere, W., Gorfinkel, I., Korhonen, T., Leung, E., McNeil, S. A., Oostvogels, L., Rombo, L., Smetana, J., Weckx, L., Yeo, W., & Heineman, T. C.
- Affiliations
- The University of Sydney (AU)
- Uppsala University (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-09-15
- Volume
- 375
- Issue
- 11
- Pages
- 1019-1032
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2519957152
- Cited by
- 1,070
- References
- 31
- Citations by year
- 2026: 96 · 2025: 124 · 2024: 107 · 2023: 97 · 2022: 91 · 2021: 120 · 2020: 94 · 2019: 117 · 2018: 138 · 2017: 75 · 2016: 11
- FWCI
- 106.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Online (University of Wollongong) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Sanofi
- Novo Nordisk
- Astellas Pharma
- H. Lundbeck A/S
- Sanofi Pasteur
- Topics
- Health Sciences › Medicine › Infectious Diseases › Herpesvirus Infections and Treatments
- Health Sciences › Medicine › Epidemiology › Cytomegalovirus and herpesvirus research
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- herpes zoster, postherpetic neuralgia, vaccine efficacy, older adults, AS01B adjuvant, vaccine safety, herpes zoster incidence, vaccine adverse events, immunosenescence, immunogenicity
- MeSH terms
- Aged, Aged, 80 and over, Double-Blind Method, Female, Herpes Zoster, Humans, Male, Middle Aged, Risk, Vaccines, Subunit, Neuralgia, Postherpetic, Herpes Zoster Vaccine, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
